- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01972022
TRANSFORM OCT TRiple Assessment of Neointima Stent FOrmation to Reabsorbable polyMer With Optical Coherence Tomography (TRANSFORM)
July 2, 2015 updated by: GGuagliumi, A.O. Ospedale Papa Giovanni XXIII
A Prospective Optical Coherence Tomography (OCT) Study on Coronary Vessel Wall Response to Stent Eluting Everolimus From a Biodegradable Polymer (EES SYNERGY™) Compared With Stent Eluting Zotarolimus From a Durable Polymer (ZES, RESOLUTE Integrity™).
First prospective randomized controlled study to evaluate in an 'all-comers' population with coronary artery disease whether treatment with a novel everolimus eluting stent (EES) with a biodegradable polymer is superior to a durable polymer zotarolimus eluting stent (ZES), with respect to the long term vascular response to treatment These data are important to ascertain the superiority of a new generation DES with bioabsorbable polymer coating to reduce the long term development of in-stent neoatherosclerosis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
During the last decade a considerable clinical experience has been accumulated with the use of drug eluting coronary stents with durable polymers, that permanently cover the metallic stent scaffold, allowing the local delivery of anti-restenotic agents.
However durable polymers have been associated with an increased risk of late and very late stent thrombosis and the anticipated development of in stent neo-atherosclerosis.
Since permanent polymer coatings may have pro-inflammatory effects, with delayed healing and prolonged endothelial dysfunction, current research on DES has focused on the use of biodegradable polymer coatings, which disappear after a short period of drug-release (3-4 months).
Current clinical guidelines recommend at least 6-12 months of dual antiplatelet therapy (DAPT) after DES implantation,in order to prevent ST.
Recent data obtained by pooled analyses of ZES, support a significant reduction of the DAPT to the same range used with bare metal stents.
The substantial delays in DES healing observed from multiple human pathology series and in-vivo studies using Optical Coherence Tomography (OCT) were not assessed as risk factors for prolonged used of DAPT.
However different patient cohorts might have different responses to stent implantation.
In addition, there is no comparative evidence on long term development of neo-atherosclerosis in bioabsorbable versus permanent polymer DES.
OCT allows precise assessment of stent strut apposition and coverage and accurate measures of different tissue components of neoatherosclerosis.
This study is the first attempting to characterize the early and late vascular responses to novel bioabsorbable polymer EES (SYNERGY™) compared with a permanent polymer benchmark novel generation ZES (RESOLUTE INTEGRITY™) .The stent comparator has been selected due to the large use across the interventional cardiology community and the recent approval from European Regulators Authorities to update the CE (Conformité Européenne) mark labeling to only one-month duration of dual anti-platelet therapy.
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bergamo, Italy, 24127
- A.O. Ospedale Papa Giovanni XXIII
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is ≥18 years of age;
- Subject has stable angina or acute coronary syndrome (including acute myocardial infarction) with evidence of coronary ischemia and de novo atherosclerotic coronary artery disease in multiple vessels with an indication for stent implantation;
- Target lesion stenosis is ≥ 70% (visual estimate)
- All target lesions require treatment with stents having diameters from 2.25 mm to 4.0 mm (visual estimate)
- Target lesion length ≥10 mm and ≤50 mm for each target lesion(s)
- Subject must sign Ethics Committee approved informed consent prior to undergoing any study specific procedure;
- Subject must be willing and able to comply with specified follow-up schedule.
Exclusion Criteria:
- Unprotected left main coronary disease;
- Chronic total occlusion;
- Severe calcified target lesion(s) which cannot be, in the investigator's opinion, successfully treated;
- Significant angulation in the target vessel that, in the Investigator's opinion, may preclude stent delivery and deployment;
- Bifurcation disease involving a side branch ≥ 2.5 mm in diameter;
- Restenotic lesions;
- Target lesion(s) within a coronary bypass graft (e.g., saphenous vein or arterial graft);
- In the Investigator's opinion, the lesion is not suitable for stenting or OCT imaging (e.g. extreme tortuosity, very distal lesions).
- Documented left ventricular ejection fraction ≤30%;
- Serum creatinine > 2.0 mg/dl at the time of treatment;
- Recipient of heart transplant;
- Subject with malignancies or other comorbidities (i.e. severe liver, renal, pulmonary, pancreatic disease) with life expectancy less than 18 months or that may results in protocol non-compliance;
- Known bleeding or hyper-coagulable disorder;
- Known allergy to stent components or any antiplatelet recommended drug
- Planned medical or surgical procedures requiring modification of DAPT regimen within 3 months after the index procedure;
- Women of childbearing potential without negative pregnancy test within 7 days before enrollment
- Currently participating in an investigational study that has not completed the primary endpoint or that clinically interferes with the study endpoints
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EES SYNERGY™
coronary artery lesions treated with Bioabsorbable Polymer EES
|
percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
|
ACTIVE_COMPARATOR: ZES, RESOLUTE Integrity™
coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
|
percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
percentage of frames with in stent-lipid laden neointima, neovascularization, calcification and thin-cap fibro-atheroma (TFCA)
Time Frame: 18 months
|
OCT finding of neoatherosclerosis, counted as percentage of frames with in stent-lipid laden neointima, neovascularization, calcification and thin-cap fibro-atheroma (TFCA) (18 month primary end-point)
|
18 months
|
length of consecutive frames with uncovered struts
Time Frame: 3 and 18 months
|
OCT derived maximum length of consecutive frames with uncovered struts in the two stent arms at 3 and 18 month (3 month primary end-point and 18 months co-primary end-points)
|
3 and 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
percent well apposed struts at implant without neointima
Time Frame: 3 and 18 months
|
OCT derived proportion of well apposed struts at implant without neointima (% uncovered struts) at 3 and 18 months
|
3 and 18 months
|
Acquired stent malapposition
Time Frame: 3 and 18 moths
|
Number and extent (max area-volume) of newly acquired malapposed struts at 3 and 18 months.
|
3 and 18 moths
|
OCT derived abnormal intraluminal tissue
Time Frame: 3 and 18 months
|
Presence of any abnormal intraluminal protruding mass at 3 and 18 months
|
3 and 18 months
|
percentage OCT frames with uncovered struts
Time Frame: 3 and 18 months
|
Number/percentage of OCT frames with > 30% uncovered struts at 3 and 18 months
|
3 and 18 months
|
Neointimal tissue thickness
Time Frame: 3 and 18 months
|
OCT calculated thickness of tissue covering stents at 3 and 18 months
|
3 and 18 months
|
OCT derived percentage of frames with mature neointima
Time Frame: 3 and 18 months
|
Percentage of frames with evidence of mature neointimal coverage in the two stent arms
|
3 and 18 months
|
OCT derived tissue heterogeneity in neointima deposition
Time Frame: 3 and 18 moths
|
Segmental tissue heterogeneity in neointima deposition across the entire stent length (as assessed by OCT tissue properties parameters - including normalized intensity, attenuation, tissue contrast) at 3 and 18 months
|
3 and 18 moths
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Giulio Guagliumi, MD, A.O. Papa Giovanni XXIII, Cardiovascular Department
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (ANTICIPATED)
March 1, 2016
Study Completion (ANTICIPATED)
September 1, 2016
Study Registration Dates
First Submitted
October 24, 2013
First Submitted That Met QC Criteria
October 24, 2013
First Posted (ESTIMATE)
October 30, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
July 3, 2015
Last Update Submitted That Met QC Criteria
July 2, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TRANSFORM 1207/2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Lesions
-
OrbusNeichCompletedCoronary Artery LesionsAustralia
-
Biotronik AGCompletedDe Novo and Re-stenosed Coronary Artery LesionsSwitzerland, Netherlands, Israel, Spain, Latvia, Germany, Austria, Belgium, France, Ireland
-
Abbott Medical DevicesCompletedCoronary Artery LesionsUnited States
-
Sección Hemodinamica y Cardiologia IntervencionistaUnknownCoronary Artery Lesions With Implantation of Coronary DeviceSpain
-
Tryton Medical, Inc.CompletedCoronary Atherosclerosis of Native Coronary Artery | Bifurcation Lesions: de Novo Lesions of the Main and Side Branch of Native Coronary ArteryUnited States
-
Chinese PLA General HospitalUnknown
-
Seoul National University HospitalCompletedBifurcating Coronary Artery Lesions | Main Branch Stent Implantation | Side Branch JailingKorea, Republic of
-
Yonsei UniversityUnknownCoronary Artery Obstructive Disease | Chronic Total Occlusion LesionsKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...CompletedOptical Coherence Tomography (OCT) | Percutaneous Coronary Intervention (PCI) | Single-Photon Emission Computed Tomography (SPECT) | Coronary Angiography (CAG) | Borderline Coronary Artery LesionsChina
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
Clinical Trials on EES SYNERGY™
-
Deutsches Herzzentrum MuenchenUnknownTest Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)Coronary StenosisGermany
-
Jung-min AhnCardioVascular Research Foundation, KoreaRecruitingMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Artery Disease | Coronary DiseaseKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Volcano CorporationCompletedHeart Diseases | Cardiovascular Diseases | 3 Vessel Coronary Artery DiseaseNetherlands, Poland, Spain, United Kingdom
-
AtriCure, Inc.RecruitingPostural Tachycardia Syndrome | Inappropriate Sinus TachycardiaBelgium
-
AtriCure, Inc.CompletedPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationUnited States
-
Nandan Lad, M.D., Ph.D.RecruitingSpinal Cord Injury at T1-T12 Level | Traumatic Thoracic Spinal Cord Contusion | Thoracic Spinal Cord Trauma | Traumatic Thoracic Spinal Cord Laceration | Post-Traumatic Thoracic Myelopathy | Traumatic Thoracic Spinal Cord MyelopathyUnited States
-
AtriCure, Inc.Enrolling by invitationAtrial Fibrillation
-
University of ZurichCompletedST-elevation Myocardial Infarction | Multivessel Coronary DiseaseSwitzerland
-
Buddhist Tzu Chi General HospitalRecruiting
-
Keimyung University Dongsan Medical CenterUnknownMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Arterial Occlusive DiseasesKorea, Republic of